dc.contributor.author |
Calvo-Flores Guzmán, Beatriz |
en |
dc.contributor.author |
Vinnakota, Chitra |
en |
dc.contributor.author |
Govindpani, Karan |
en |
dc.contributor.author |
Waldvogel, Henry |
en |
dc.contributor.author |
Faull, Richard |
en |
dc.contributor.author |
Kwakowsky, Andrea |
en |
dc.date.accessioned |
2018-12-10T20:25:52Z |
en |
dc.date.issued |
2018-09 |
en |
dc.identifier.citation |
Journal of neurochemistry 146(6):649-669 Sep 2018 |
en |
dc.identifier.issn |
0022-3042 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/44995 |
en |
dc.description.abstract |
Glutamatergic and cholinergic dysfunction are well-attested features of Alzheimer's disease (AD), progressing with other pathological indices of the disorder and exacerbating neuronal and network dysfunction. However, relatively little attention has been paid to the inhibitory component of the excitatory/inhibitory (E/I) network, particularly dysfunction in the gamma-aminobutyric acid (GABA) signaling system. There is growing evidence in support of GABAergic remodeling in the AD brain, potentially beginning in early stages of disease pathogenesis, and this could thus be a valid molecular target for drug development and pharmacological therapies. Several GABAergic drugs have been tested for efficacy in attenuating or reversing various features and symptoms of AD, and this could represent a novel path by which we might address the growing need for more effective and benign therapies. |
en |
dc.format.medium |
Print-Electronic |
en |
dc.language |
eng |
en |
dc.relation.ispartofseries |
Journal of neurochemistry |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
https://authorservices.wiley.com/author-resources/Journal-Authors/licensing/self-archiving.html |
en |
dc.subject |
Animals |
en |
dc.subject |
Humans |
en |
dc.subject |
Alzheimer Disease |
en |
dc.subject |
gamma-Aminobutyric Acid |
en |
dc.subject |
Signal Transduction |
en |
dc.title |
The GABAergic system as a therapeutic target for Alzheimer's disease. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1111/jnc.14345 |
en |
pubs.issue |
6 |
en |
pubs.begin-page |
649 |
en |
pubs.volume |
146 |
en |
dc.rights.holder |
Copyright: International Society for Neurochemistry |
en |
dc.identifier.pmid |
29645219 |
en |
pubs.end-page |
669 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
en |
pubs.subtype |
Review |
en |
pubs.subtype |
Journal Article |
en |
pubs.elements-id |
736128 |
en |
pubs.org-id |
Academic Services |
en |
pubs.org-id |
Examinations |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Anatomy and Medical Imaging |
en |
dc.identifier.eissn |
1471-4159 |
en |
pubs.record-created-at-source-date |
2018-04-13 |
en |
pubs.dimensions-id |
29645219 |
en |